Can Fite Biopharma Ltd ADR (CANF) — Working Capital to Net Assets Ratio
Can Fite Biopharma Ltd ADR (CANF) has a Working Capital to Net Assets ratio of 120.0% as of December 2025. Working capital of $6.71 Million (current assets of $9.44 Million minus current liabilities of $2.73 Million) is measured against net assets of $5.59 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See financial agility of Can Fite Biopharma Ltd ADR to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Can Fite Biopharma Ltd ADR Working Capital to Net Assets (2011–2025)
This chart shows how Can Fite Biopharma Ltd ADR's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of December 2025, the ratio stands at 120.0%, reflecting working capital of $6.71 Million against net assets of $5.59 Million USD. See operational self-sufficiency of Can Fite Biopharma Ltd ADR to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Can Fite Biopharma Ltd ADR (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Can Fite Biopharma Ltd ADR from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Can Fite Biopharma Ltd ADR stock valuation.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 120.0% | $6.71 Million | $5.59 Million | $9.44 Million | $2.73 Million | ▼ -7.5 pp |
| 2024 | 127.5% | $6.93 Million | $5.44 Million | $8.98 Million | $2.05 Million | ▲ +1.1 pp |
| 2023 | 126.3% | $7.89 Million | $6.24 Million | $9.91 Million | $2.02 Million | ▼ -22.5 pp |
| 2022 | 148.8% | $6.66 Million | $4.47 Million | $9.16 Million | $2.50 Million | ▲ +28.3 pp |
| 2021 | 120.6% | $17.34 Million | $14.38 Million | $20.07 Million | $2.73 Million | ▼ -13.3 pp |
| 2020 | 133.9% | $8.13 Million | $6.07 Million | $9.40 Million | $1.27 Million | ▼ -24.7 pp |
| 2019 | 158.6% | $3.87 Million | $2.44 Million | $7.14 Million | $3.27 Million | ▼ -0.1 pp |
| 2018 | 158.7% | $4.78 Million | $3.02 Million | $7.90 Million | $3.12 Million | ▼ -7.3 pp |
| 2017 | 166.0% | $5.07 Million | $3.05 Million | $6.87 Million | $1.80 Million | ▼ -30.2 pp |
| 2016 | 196.2% | $7.60 Million | $3.87 Million | $10.10 Million | $2.50 Million | ▲ +45.4 pp |
| 2015 | 150.8% | $15.76 Million | $10.44 Million | $17.53 Million | $1.78 Million | ▲ +24.5 pp |
| 2014 | 126.3% | $8.66 Million | $6.86 Million | $10.15 Million | $1.48 Million | ▲ +26.7 pp |
| 2013 | 99.7% | $4.44 Million | $4.46 Million | $6.58 Million | $2.14 Million | ▼ -3.7 pp |
| 2012 | 103.4% | $-732.35K | $-707.99K | $1.59 Million | $2.32 Million | ▼ -2.2 pp |
| 2011 | 105.6% | $3.48 Million | $3.29 Million | $4.83 Million | $1.35 Million | — |